XLO Xilio Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 18 May 2022 Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference

   WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 2:30 p.m. ET.
   

   A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.

   About Xilio Therapeutics
   Xilio Therapeutics is a clinical-stage biotechnology company…

   View Full Article
2. 17 May 2022 Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer

   WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Stacey Davis has been appointed as chief business officer to further the company's corporate and business development strategy that will be central to its next stage of growth.
   

   "As an accomplished life science leader, Stacey brings significant strategic business experience building successful portfolios in oncology and immunology with an in-depth knowledge of the real-world patient and physician experience," said René Russo, Pharm.D., president and chief executive officer of Xilio. "Her broad operational and business development…

   View Full Article
3. 12 May 2022 Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results

   Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022
   

   On track with plans to submit IND for XTX301, a tumor-selective IL-12, in second half of 2022

   Strong financial position with $177 million in cash and cash equivalents as of March 31, 2022, with cash runway anticipated into first half of 2024

   WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced pipeline and business highlights and reported financial results for the first quarter ended March 31, 2022.

   "Leveraging our…

   View Full Article
4. 07 April 2022 Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

   WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the 21^st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 8:00 a.m. ET.
   

   A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.

   About Xilio Therapeutics
   Xilio Therapeutics is a clinical-stage biotechnology company focused…

   View Full Article
5. 01 March 2022 Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

   Initial Phase 1 Data Readouts from Clinical Trials of XTX101 and XTX202 Anticipated in 2022
   

   On Track with Plans to Submit IND for XTX301 in Second Half of 2022

   Continue to Anticipate Cash Runway into 2024 with $198.1 Million in Cash and Cash Equivalents at Year-End 2021

   WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced pipeline and business progress and reported financial results for the fourth quarter and full year ended December 31, 2021.

   "Xilio made significant pipeline and business progress in 2021, becoming a clinical-stage organization and transitioning to a publicly…

   View Full Article